Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients

Next Previous
Trial Profile

A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Faecal incontinence
  • Focus Therapeutic Use
  • Sponsors RDD Pharma

Most Recent Events

  • 05 Jul 2017 According to an RDD Pharma media release, the European Medicines Agency's Committee has granted orphan designation for RDD-0315, an investigational drug for the treatment of fecal incontinence in patients with spinal cord injury.
  • 24 May 2016 Primary endpoint (The number of fecal incontinence episodes in 12 hours post drug administration) has been met according to the results presented at the Digestive Disease Week 2016.
  • 24 May 2016 Results assessing the effect of oxymetazoline on fecal incontinence presented at the Digestive Disease Week 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top